3/31
04:43 pm
scyx
SCYNEXIS, Inc. (SCYX) Discusses Transformative Asset Acquisition and Strategic Shift Toward ADPKD Therapeutics Transcript [Seeking Alpha]
Medium
Report
SCYNEXIS, Inc. (SCYX) Discusses Transformative Asset Acquisition and Strategic Shift Toward ADPKD Therapeutics Transcript [Seeking Alpha]
3/31
08:13 am
scyx
Poxel Announces the Sale of PXL770 to Scynexis for a Total Amount of up to $196 Million [Yahoo! Finance]
High
Report
Poxel Announces the Sale of PXL770 to Scynexis for a Total Amount of up to $196 Million [Yahoo! Finance]
3/31
07:50 am
scyx
SCYNEXIS announces $40M private placement [Seeking Alpha]
High
Report
SCYNEXIS announces $40M private placement [Seeking Alpha]
3/31
07:10 am
scyx
SCYNEXIS Completes Transformative Acquisition of PXL-770, an innovative, highly selective, direct AMPK activator for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD) [Yahoo! Finance]
High
Report
SCYNEXIS Completes Transformative Acquisition of PXL-770, an innovative, highly selective, direct AMPK activator for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD) [Yahoo! Finance]
3/31
07:06 am
scyx
Poxel Announces the Sale of PXL770 to Scynexis for a Total Amount of up to $196 Million
Medium
Report
Poxel Announces the Sale of PXL770 to Scynexis for a Total Amount of up to $196 Million
3/31
07:02 am
scyx
SCYNEXIS Announces $40.0 Million Private Placement [TheStreet.com]
Low
Report
SCYNEXIS Announces $40.0 Million Private Placement [TheStreet.com]
3/31
06:45 am
scyx
SCYNEXIS Announces $40.0 Million Private Placement
High
Report
SCYNEXIS Announces $40.0 Million Private Placement
3/31
06:40 am
scyx
SCYNEXIS Completes Transformative Acquisition of PXL-770, an innovative, highly selective, direct AMPK activator for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)
High
Report
SCYNEXIS Completes Transformative Acquisition of PXL-770, an innovative, highly selective, direct AMPK activator for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)
3/31
01:07 am
scyx
High
Report
3/23
01:04 am
scyx
Medium
Report
3/15
01:05 am
scyx
Medium
Report
3/9
08:05 pm
scyx
SCYNEXIS (SCYX) had its "buy" rating reaffirmed by Brookline Capital Acquisition Corp..
Medium
Report
SCYNEXIS (SCYX) had its "buy" rating reaffirmed by Brookline Capital Acquisition Corp..
3/4
05:42 pm
scyx
Scynexis: Q4 Earnings Snapshot [Yahoo! Finance]
Medium
Report
Scynexis: Q4 Earnings Snapshot [Yahoo! Finance]
3/4
04:58 pm
scyx
SCYNEXIS Reports Full Year 2025 Financial Results and Provides Corporate Update [Yahoo! Finance]
Medium
Report
SCYNEXIS Reports Full Year 2025 Financial Results and Provides Corporate Update [Yahoo! Finance]
3/4
04:20 pm
scyx
SCYNEXIS Reports Full Year 2025 Financial Results and Provides Corporate Update
Low
Report
SCYNEXIS Reports Full Year 2025 Financial Results and Provides Corporate Update
2/26
08:34 am
scyx
SCYNEXIS Announces First Participants Dosed in a Phase 1 Single Ascending Dose and Multiple Ascending Dose Trial of Intravenous SCY-247 [Yahoo! Finance]
Medium
Report
SCYNEXIS Announces First Participants Dosed in a Phase 1 Single Ascending Dose and Multiple Ascending Dose Trial of Intravenous SCY-247 [Yahoo! Finance]
2/26
08:23 am
scyx
SCYNEXIS Announces First Participants Dosed in a Phase 1 Single Ascending Dose and Multiple Ascending Dose Trial of Intravenous SCY-247
High
Report
SCYNEXIS Announces First Participants Dosed in a Phase 1 Single Ascending Dose and Multiple Ascending Dose Trial of Intravenous SCY-247
1/28
08:00 am
scyx
SCYNEXIS Announces Presentations Highlighting the Potent Antifungal Activity of its Second-Generation Fungerp, SCY-247 Against Drug-Resistant Fungi, at the Inaugural Interdisciplinary Meeting on Antimicrobial Resistance and Innovation (IMARI)
Medium
Report
SCYNEXIS Announces Presentations Highlighting the Potent Antifungal Activity of its Second-Generation Fungerp, SCY-247 Against Drug-Resistant Fungi, at the Inaugural Interdisciplinary Meeting on Antimicrobial Resistance and Innovation (IMARI)
1/21
10:32 am
scyx
SCYNEXIS Receives FDA Qualified Infectious Disease Product (QIDP) and Fast Track Designations for SCY-247 [Yahoo! Finance]
Medium
Report
SCYNEXIS Receives FDA Qualified Infectious Disease Product (QIDP) and Fast Track Designations for SCY-247 [Yahoo! Finance]
1/21
08:00 am
scyx
SCYNEXIS Receives FDA Qualified Infectious Disease Product (QIDP) and Fast Track Designations for SCY-247
High
Report
SCYNEXIS Receives FDA Qualified Infectious Disease Product (QIDP) and Fast Track Designations for SCY-247